NASH

CBG: The 'Mother Cannabinoid' May Hold Key To Treating Nonalcoholic Fatty Liver Disease Symptoms
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings

NASH Recent News

Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) 
Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) is a clinical-stage biopharma developing liver and metabolic disorders therapies.
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Exclusive: Axcella Health Aims To Become The Standard Of Care
Axcella Health Inc (NASDAQ: AXLA) is a clinical-stage biotechnology company focused on endogenous metabolic modulators, or EEMs, said Axcella Health CEO Bill Hinshaw Thursday on Benzinga's YouTube show "Power Hour."<
89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference
89bio Inc (NASDAQ: ETNB) 
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
This week could see up to nine companies price their IPOs. Here is a look at the companies looking to go public this week. 
IPO Outlook For The Week: Snowflake and Amwell Lead Busy 12 IPO Lineup
Benzinga took a look at high profile IPOs coming in the second half of 2020. Six of those 13 companies could price the week of September 14. Here is a look at the 12 companies expected to go public.
Why Shares Of NASH Biotech Intercept Pharma Are Slumping
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares were retreating sharply Monday on the back of an FDA rejection of its lead non-alcoholic steatohepatitis drug.
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study
Non-alcoholic steatohepatitis biotechs are increasingly finding it difficult to make headway, and the lack of any approved therapy despite a slew of research is a testament to the challenge. 
NGM Biopharma Shares Spike Higher On Positive NASH Study Results
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Lipocine's NASH Candidate Shows Promise In Liver Fat Study